Evercore ISI lowered the firm’s price target on Health Catalyst (HCAT) to $3 from $4 and keeps an In Line rating on the shares as the firm updates estimates and makes several tactical calls in the Healthcare Technology & Distribution group ahead of Q3 earnings season.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT: